Research

Original Investigation - 

Patients with end-stage renal disease (ESRD) who receive a left ventricular assist device (LVAD) survive an average of only 16 days after implantation, according to a small study published in JAMA Internal Medicine.

Lead researcher Nisha Bansal, MD, and colleagues Susan M. Hailpern, DrPH, MS, Ronit Katz, DPhil, Yoshio N. Hall, MD, Manjula K. Tamura, MD, William Kreuter, MPA,  and Ann M. O’Hare, MD compared survival times of 155 Medicare beneficiaries with ESRD to 261 without ESRD, which was defined as having received maintenance dialysis or a kidney transplant.

Kidney drawing with eraser

Read about their findings:

Cardiovasular Business

JAMA Internal Medicine

Medscape